"You Can See Everything," the Nathan Fielder and Lance Oppenheim documentary about disgraced Theranos founder Elizabeth Holmes, shocked Hollywood with a $15 million opening weekend from just 855 theaters, proving that prestige documentaries can still draw audiences in the streaming era.

The December Films release averaged an astonishing $17,544 per theater, the highest per-screen average for any film this year and the best documentary debut since Michael Moore's "Fahrenheit 9/11" in 2004. The limited-theater strategy and word-of-mouth buzz propelled the film to the second-highest total at the domestic box office for the October 16-18 weekend, trailing only Paramount's "Street Fighter" reboot.

Elizabeth Holmes Returns to the Spotlight

The documentary arrives four years after Holmes was sentenced to 11 years in federal prison for defrauding investors out of hundreds of millions of dollars. Holmes claimed her blood-testing company Theranos could run hundreds of tests from a single finger prick, but the technology never worked as advertised.

Director Nathan Fielder, best known for HBO's "The Rehearsal" and Comedy Central's "Nathan for You," secured unprecedented access to Holmes during her final months before surrendering to federal custody in May 2022. The film includes never-before-seen footage of Holmes at home with her partner Billy Evans and their two young children, as well as extensive sit-down interviews where Holmes maintains her innocence and blames others for Theranos's collapse.

Co-director Lance Oppenheim, whose 2023 documentary "Some Kind of Heaven" explored life in a Florida retirement community, brings his signature observational style to the project. The filmmakers follow Holmes through her daily routine, capturing moments both mundane and surreal as she navigates life under house arrest while fighting her conviction on appeal.

Awards Season Buzz Builds

The box office performance positions "You Can See Everything" as a serious Oscar contender in the Best Documentary Feature category. The Academy has increasingly favored high-profile documentaries with theatrical releases, and the film's commercial success gives it momentum heading into the December qualifying period.

Critics have praised Fielder and Oppenheim's unflinching approach to their subject. The film neither fully vilifies nor exonerates Holmes, instead presenting her as a complex figure whose ambition and self-deception led to one of the biggest corporate frauds in Silicon Valley history.

The documentary includes interviews with former Theranos employees, investors who lost millions backing the company, and journalists who helped expose the fraud. Holmes herself remains the central figure, speaking at length about her vision for Theranos, her relationship with former company president Ramesh "Sunny" Balwani, and what she describes as a rush to judgment by prosecutors and the media.

Limited Release Strategy Pays Off

December Films chose a platform release strategy, opening the documentary in New York, Los Angeles, San Francisco, and select other markets before expanding to additional theaters in coming weeks. The approach capitalizes on strong reviews and word-of-mouth while building buzz ahead of a planned streaming release in early 2027.

The 855-theater opening is tiny compared to wide releases like "Street Fighter," which debuted on 4,200 screens and earned $31 million domestically. But "You Can See Everything" cost just $8 million to produce, making its $15 million opening a stunning return on investment that has already pushed the film into profitability before ancillary revenue streams like streaming and international distribution.

Theater exhibitors reported packed houses and sold-out screenings across major markets, with audiences ranging from true-crime enthusiasts to business professionals curious about the Theranos saga. The film's run time of 127 minutes allows for only two or three screenings per day at most venues, limiting total box office potential but maximizing per-show revenue.

Documentary Genre Having a Moment

The success of "You Can See Everything" comes amid a renaissance for theatrical documentaries. Earlier this year, "The Space Program," a National Geographic documentary about the 50th anniversary of the Apollo moon landing, grossed $42 million worldwide, while Alex Gibney's investigative film "The Bitcoin Files" earned $28 million.

Streaming platforms have trained audiences to expect documentaries at home, but premium releases with must-see subject matter or acclaimed filmmakers continue to draw viewers to theaters. The Fielder-Oppenheim collaboration benefits from both elements: a household-name subject in Holmes and two directors with devoted followings among younger, culturally engaged audiences.

The film has already sparked debate about media ethics, the criminal justice system's treatment of white-collar crime, and whether Holmes deserves sympathy or scorn. That cultural conversation seems likely to intensify as the documentary expands to additional markets in November and December, positioning it perfectly for Oscar voting season.

"You Can See Everything" expands to 1,500 theaters nationwide on October 23.